Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network

Journal of Substance Abuse Treatment

Volumn 37, Issue 3, 2009, Pages 307-312

  Knudsen, Hannah K ^a   Abraham, Amanda J ^b   Johnson, J Aaron ^b   Roman, Paul M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adoption of innovations; Buprenorphine; Clinical Trials Network; Health services research

Indexed keywords

BUPRENORPHINE; METHADONE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY PROGRAM; DETOXIFICATION; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HUMAN; OPIATE ADDICTION; ORGANIZATIONAL STRUCTURE; PREDICTION; PRIORITY JOURNAL;

BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DATA COLLECTION; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 69349089334     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2008.12.004     Document Type: Article

References (20)

1. Allison P.D. Logistic regression using the SAS System: Theory and application (1999), SAS Publishing, Cary, NC
2. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions 13 (2004) S42-S46
3. Cepeda M.S., Boston R., Farrar J.T., and Strom B.L. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology 158 (2003) 280-287
4. Ducharme L.J., and Abraham A.J. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 3 (2008) 17. http://www.substanceabusepolicy.com/content/3/1/17 (http://www.substanceabusepolicy.com/content/3/1/17)
5. Ducharme L.J., Knudsen H.K., Roman P.M., and Johnson J.A. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment 32 (2007) 321-329
6. Ducharme L.J., and Roman P.M. Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment 37 (2007) 90-94
7. Fennell M.L., and Warnecke R.B. The diffusion of medical innovations (1988), Plenum, New York
8. Hanson G.R., Leshner A.I., and Tai B. Putting drug abuse research to use in real-life settings. Journal of Substance Abuse Treatment 23 (2002) 69-70
9. Knudsen H.K., Ducharme L.J., and Roman P.M. Early buprenorphine adoption in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 30 (2006) 363-373
10. Koch A.L., Arfken C.L., and Schuster C.R. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence 83 (2006) 274-278
11. Laliberte L., Fennell M.L., and Papandonatos G. The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer. Medical Care 43 (2005) 471-479
12. In: Lamb S., Greenlick M.R., and McCarty D. (Eds). Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment (1998), National Academy Press, Washington, DC 27-55
13. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 (2005) 1090-1100
14. McCarty D., Fuller B., Kaskutas L.A., Wendt W.W., Nunes E.V., Miller M., et al. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug and Alcohol Dependence 92 (2008) 200-207
15. Mee-Lee D.L., Gartner L., Miller M.M., Shulman G.D., and Wilford B.B. Patient placement criteria for the treatment of substance-related disorders, second edition (1996), ASAM, Chevy Chase, MD
16. National Institute on Drug Abuse. National Drug Abuse Treatment Clinical Trials Network. Available at:. http://www.nida.nih.gov/CTN/protocol/brochure/2005_ctn_brochure%2010_17_05.pdf Accessed on August 28, 2008
17. Oser C.B., and Roman P.M. A categorical typology of naltrexone-adopting private substance abuse treatment centers. Journal of Substance Abuse Treatment 34 (2007) 433-442
18. Peduzzi P., Concato J., Kemper E., Holford T.R., and Feinstein A.R. A simulation study of number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology 49 (1996) 1373-1379
19. Rogers E.M. Diffusion of innovations. 5th ed. (2003), Free Press, New York
20. Saxon A.J., and McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacology & Therapeutics 108 (2005) 119-128